Repeated quinpirole treatment increases cAMP-dependent protein kinase activity and CREB phosphorylation in nucleus accumbens and reverses quinpirole-induced sensorimotor gating deficits in rats

被引:30
作者
Culm, KE
Lugo-Escobar, N
Hope, BT
Hammer, RP
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol, Boston, MA 02111 USA
[2] Tufts Univ, Sch Med, Dept Expt Therapeut, Boston, MA 02111 USA
[3] Tufts Univ, Sch Med, Dept Neurosci Anat & Psychiat, Boston, MA 02111 USA
[4] NIDA, Behav Neurosci Branch, Intramural Res Program, Baltimore, MD USA
关键词
prepulse inhibition; schizophrenia; D-2-like receptors; PKA; phospho-CREB; nucleus accumbens;
D O I
10.1038/sj.npp.1300483
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Sensorimotor gating, which is severely disrupted in schizophrenic patients, can be measured by assessing prepulse inhibition of the acoustic startle response (PPI). Acute administration of D-2-like receptor agonists such as quinpirole reduces PPI, but tolerance occurs upon repeated administration. In the present study, PPI in rats was reduced by acute quinpirole (0.1 mg/kg, s.c.), but not following repeated quinpirole treatment once daily for 28 days. Repeated quinpirole treatment did not alter the levels of basal-, forskolin- (5 muM), or SKF 82958- (10 muM) stimulated adenylate cyclase activity in the nucleus accumbens (NAc), but significantly increased cAMP-dependent protein kinase (PKA) activity. Phosphorylation of cAMP response element-binding protein ( CREB) was significantly greater in the NAc after repeated quinpirole treatment than after repeated saline treatment with or without acute quinpirole challenge. Activation of PKA by intra-accumbens infusion of the cAMP analog, Sp-cAMPS, prevented acute quinpirole-induced PPI disruption, similar to the behavioral effect observed following repeated quinpirole treatment. Thus, repeated quinpirole treatment increases NAc PKA activity and CREB phosphorylation, and this neuroadaptive response might facilitate the recovery of sensorimotor gating in schizophrenia.
引用
收藏
页码:1823 / 1830
页数:8
相关论文
共 34 条
[1]   AUTORADIOGRAPHIC LOCALIZATION OF DOPAMINE-D1 AND D2-RECEPTORS IN RAT NUCLEUS-ACCUMBENS - RESISTANCE TO DIFFERENTIAL REARING CONDITIONS [J].
BARDO, MT ;
HAMMER, RP .
NEUROSCIENCE, 1991, 45 (02) :281-290
[2]   CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli [J].
Barrot, M ;
Olivier, JDA ;
Perrotti, LI ;
DiLeone, RJ ;
Berton, O ;
Eisch, AJ ;
Impey, S ;
Storm, DR ;
Neve, RL ;
Yin, JC ;
Zachariou, V ;
Nestler, EJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11435-11440
[3]   Dopamine agonists in schizophrenia: A review [J].
Benkert, O ;
MullerSiecheneder, F ;
Wetzel, H .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1995, 5 :43-53
[4]  
Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911
[5]   The disruptive effect of cocaine on prepulse inhibition is prevented by repeated administration in rats [J].
Byrnes, JJ ;
Hammer, RP .
NEUROPSYCHOPHARMACOLOGY, 2000, 22 (05) :551-554
[6]   Regulation of cocaine reward by CREB [J].
Carlezon, WA ;
Thome, J ;
Olson, VG ;
Lane-Ladd, SB ;
Brodkin, ES ;
Hiroi, N ;
Duman, RS ;
Neve, RL ;
Nestler, EJ .
SCIENCE, 1998, 282 (5397) :2272-2275
[7]   Recovery of sensorimotor gating without G protein adaptation after repeated D2-like dopamine receptor agonist treatment in rats [J].
Culm, KE ;
Hammer, RP .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) :487-494
[8]   Reduced Gi and Go protein function in the rat nucleus accumbens attenuates sensorimotor gating deficits [J].
Culm, KE ;
Lim, AM ;
Onton, JA ;
Hammer, RP .
BRAIN RESEARCH, 2003, 982 (01) :12-18
[9]   Synaptic plasticity and mood disorders [J].
Duman, RS .
MOLECULAR PSYCHIATRY, 2002, 7 (Suppl 1) :S29-S34
[10]   Differential effects of haloperidol and clozapine on [3H]cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain [J].
Dwivedi, Y ;
Rizavi, HS ;
Pandey, GN .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :197-209